STOCK TITAN

NEOG (NEOG) Form 4: Director Capello Adds 2,071 Shares

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Jeffrey D. Capello, a director of Neogen Corporation (NEOG), had 2,071 restricted stock units vest and settle on 10/07/2025.

The settlement converted the RSUs into 2,071 shares of common stock at an indicated unit price of $5.63, bringing his total beneficial ownership to 28,700 shares following the transaction.

Positive

  • 2,071 RSUs vested and settled into common stock on 10/07/2025
  • Beneficial ownership increased to 28,700 shares after the settlement

Negative

  • None.

Insights

Director received and settled vested RSUs into 2,071 shares on 10/07/2025.

Vesting and settlement of restricted stock units is a routine executive compensation event that increases the reporting person's direct share count by 2,071 shares. The filing shows each RSU converted to one share and a reference per-share value of $5.63, but it does not state cash proceeds or tax withholding details.

Key dependencies are standard vesting schedules and company compensation practices; the transaction is disclosed under Section 16 reporting rules and should be monitorable via subsequent filings for any sales or additional grants within the year.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAPELLO JEFFREY D

(Last) (First) (Middle)
C/O NEOGEN CORP.
620 LESHER PLACE

(Street)
LANSING MI 48912

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEOGEN CORP [ NEOG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/07/2025 M 2,071 A $5.63 28,700 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $5.63 10/07/2025 M 2,071 10/07/2025 10/07/2025 Common Stock 2,071 $5.63 0 D
Explanation of Responses:
Remarks:
Each RSU is the economic equivalent of one share of common stock. On October 7, 2025, these RSUs vested and were settled for an equal number of shares of common stock.
Christopher Sefcheck (Attorney in Fact) 10/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NEOG director Jeffrey D. Capello report on Form 4?

The Form 4 reports that 2,071 RSUs vested and were settled for 2,071 shares on 10/07/2025, with an indicated unit price of $5.63.

How many shares does Jeffrey D. Capello beneficially own after the transaction?

He beneficially owns 28,700 shares following the reported settlement.

Was this transaction a purchase or a vesting/settlement event for NEOG?

This was a vesting and settlement of restricted stock units (RSUs), reported with transaction code M indicating a conversion/settlement.

What date did the RSUs vest and settle for NEOG's director?

The RSUs vested and were settled on 10/07/2025.

What price is shown on the Form 4 for the settled RSUs?

The Form 4 lists a price of $5.63 per share for the settled RSUs.
Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Latest News

NEOG Latest SEC Filings

NEOG Stock Data

1.55B
215.36M
0.85%
112.78%
8.46%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
LANSING